anistreplase

(redirected from Eminase)

anistreplase

 [an″is-trep´lās]
a thrombolytic agent primarily used to clear coronary vessel occlusions associated with myocardial infarction; administered intravenously.

anistreplase

/an·is·trep·lase/ (an″is-trep´lās) a thrombolytic agent used to clear coronary vessel occlusions associated with myocardial infarction.

anistreplase

a plasminogen activator.
indication This drug is used in acute MI for lysis of coronary artery thrombi.
contraindications Known hypersensitivity to this drug or streptokinase; active internal bleeding; intraspinal or intracranial surgery; central nervous system neoplasms; severe, uncontrolled hypertension; cerebral embolism; thrombosis; hemorrhage; recent trauma; or history of cerebrovascular accident all prohibit the use of this drug.
adverse effects Adverse effects of this drug include headache, fever, sweating, agitation, dizziness, paresthesia, tremor, vertigo, hypotension, conduction disorders, nausea, vomiting, decreased hematocrit, surface bleeding, rash, urticaria, phlebitis at the injection site, itching, flushing, low back pain, arthralgia, altered respirations, and dyspnea. Life-threatening side effects include intracranial hemorrhage, dysrhythmias, GI bleeding, genitourinary bleeding, intracranial bleeding, retroperitoneal bleeding, thrombocytopenia, bronchospasm, lung edema, and anaphylaxis.

anistreplase

See APSAC.

anistreplase

A clot-dissolving drug used to try to re-establish blood flow in the heart muscle in the early treatment of heart attacks. A brand name is Eminase.
References in periodicals archive ?
The pricing decision also has left the product open to vicious competition from $1,700-a-dose Eminase, produced by SmithKline Beecham, and Astra Kabi's streptokinase, priced at $200 a dose.
That's an interesting choice of figures, given that your Activase, priced at $2,200 per dose, is facing some competition from $1,700-a-dose Eminase, produced by Smithkline Beechman, and streptokinase, a $200-a-dose product put out by Astra Kabi.
Researchers at Oxford University report that the frequency of strokes in a group they studied was three for every 1,000 patients who were treated with streptokinase, compared with six in 1,000 who took Eminase and seven of 1,000 who used tPA.
We see sales of Tagamet, its topselling antiulcer drug, holding steady at $1 billion, while newer drugs (most notably Augmentin, Eminase, Paroxetin and Relifex) should bolster drug sales and margins.
With this in mind, it would seem that Eminase could get approval this quarter.